Evotec has been a frontrunner in hit identification and industry-standard high throughput screening for partners since 1998, resulting in extensive knowledge accumulation over a range of different modalities, target class families and cellular phenotypic signatures. Over the past 5 years, Evotec has invested over 12 million euros in its HTS and hit identification infrastructure to offer an array of state-of-the-art technologies and automated screening platforms, enabling generation of high-quality hits delivered in lightning speed. Our well-curated and high-quality compound collections of >850,000 compounds provide access to a diverse and novel biologically relevant chemical space for hit identification. Evotec has been successful in generating tractable hits for historically considered undruggable targets, thanks to our innovations in structural biology, chemistry and drug design expertise, along with technological advances.